Lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) affect the lives of over 400 million people worldwide and costs the European Union alone more than 56 billion euros per year. Current therapies to treat these diseases are inadequate and the urgent need to develop tools to predict how these diseases are likely to progress and respond to treatment is widely recognised.

Workplan

The AirPROM (Airway Disease Predicting Outcomes through Patient Specific Computational Modelling) consortium brings together existing clinical consortia (EvA FP7, U-BIOPRED IMI and BTS Severe Asthma), with expertise in physiology, radiology, image analysis, bioengineering, data harmonization, security and ethics, computational modeling and systems biology. This broad multi discipline approach will enable us to develop an integrated multi-scale airways model.

Learn more about the individual work packages.

Aims
AirPROM has an extensive exploitation plan, involving professionals and patients that will ‘develop’ and ‘use’ the technologies emerging from this project. AirPROM aims to bridge the gaps in our clinical management of airways disease, by providing validated models that predict disease progression and response to treatment. The result could revolutionise the effectiveness of the treatment patients receive through personalising that treatment.

Supporting information
AirPROM also aims to leave a valuable legacy of research data for future research work. A sustainable data storage exchange and processing facility will support a knowledge management infrastructure. This will include storage of clinical, physiological, genetic, and imaging data which can then be used in further analysis within in the project and for future research work in the field. This will enable a cross discipline resource that facilitates information flow and leaves a substantial data legacy after the project has ended.